A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team.

Pediatrics

Volumn 103, Issue 4, 1999, Pages

  Kline, M W ^a   Blanchard, S ^a   Fletcher, C V ^a   Shenep, J L ^a   McKinney Jr , R E ^a   Brundage, R C ^a   Culnane, M ^a   Van Dyke, R B ^a   Dankner, W M ^a   Kovacs, A ^a   McDowell, J A ^a   Hetherington, S ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ADOLESCENT; ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; ISOLATION AND PURIFICATION; MALE; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFANT; MALE; RNA, VIRAL;

EID: 0033113582     PISSN: None     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.103.4.e47     Document Type: Article

References (0)